We are live on
!
Find out more
VCG
Vantage Consulting Group Portfolio holdings
AUM
$19.7M
1-Year Est. Return
280.87%
This Fund
S&P 500
This Quarter
Est. Return
+17.65%
1 Year Est. Return
+280.87%
3 Year Est. Return
+261.08%
5 Year Est. Return
+180.34%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
–
Cap. Flow
+$1.06B
Cap. Flow
% of AUM
86.51%
Top 10 Holdings %
Top 10 Hldgs %
94.5%
Holding
1,884
New
1,883
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$911M |
| 2 |
ADC Therapeutics
ADCT
|
+$55.1M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$25.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.96M |
| 5 |
Kroger
KR
|
+$366K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.04% |
| 2 | Technology | 0.89% |
| 3 | Consumer Discretionary | 0.79% |
| 4 | Industrials | 0.61% |
| 5 | Consumer Staples | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Orthofix Medical
OFIX
$496M
| $75K | 0.01% |
+1,746
| New | +$63.8K |
|
277
Oracle
ORCL
$420B
| $75K | 0.01% |
+1,154
| New | +$68.7K |
|
278
Regenxbio
RGNX
$638M
| $75K | 0.01% |
+1,652
| New | +$57.7K |
|
279
Zoetis
ZTS
$31.9B
| $75K | 0.01% |
+454
| New | +$73.8K |
|
280
AbbVie
ABBV
$433B
| $74K | 0.01% |
+687
| New | +$66K |
|
281
Biogen
BIIB
$29.8B
| $74K | 0.01% |
+303
| New | +$78.2K |
|
282
Bristol-Myers Squibb
BMY
$134B
| $74K | 0.01% |
+1,201
| New | +$73.8K |
|
283
Etsy
ETSY
$7.89B
| $74K | 0.01% |
+418
| New | +$62.9K |
|
284
Gen Digital
GEN
$16.9B
| $74K | 0.01% |
+3,554
| New | +$71.8K |
|
285
Glaukos
GKOS
$10.1B
| $74K | 0.01% |
+978
| New | +$61.8K |
|
286
Paycom
PAYC
$7.86B
| $74K | 0.01% |
+164
| New | +$65.4K |
|
287
Power Integrations
POWI
$3.37B
| $74K | 0.01% |
+910
| New | +$61.8K |
|
288
Regeneron Pharmaceuticals
REGN
$78.2B
| $74K | 0.01% |
+153
| New | +$82.6K |
|
289
Xylem
XYL
$27.8B
| $74K | 0.01% |
+726
| New | +$68.2K |
|
|
CKH
290
DELISTED
Seacor Holdings Inc.
CKH
| $74K | 0.01% |
+1,779
| New | +$62.4K |
|
291
Amgen
AMGN
$204B
| $73K | 0.01% |
+319
| New | +$73.5K |
|
292
eBay
EBAY
$47.6B
| $73K | 0.01% |
+1,444
| New | +$73.7K |
|
293
IDEX
IEX
$17.2B
| $73K | 0.01% |
+367
| New | +$69.8K |
|
294
Ingersoll Rand
IR
$34.1B
| $73K | 0.01% |
+1,603
| New | +$66.3K |
|
295
Southwest Airlines
LUV
$23B
| $73K | 0.01% |
+1,566
| New | +$67.8K |
|
296
O'Reilly Automotive
ORLY
$73.3B
| $73K | 0.01% |
+2,415
| New | +$72.9K |
|
297
Pentair
PNR
$10.9B
| $73K | 0.01% |
+1,384
| New | +$71K |
|
298
Vicor
VICR
$9.85B
| $73K | 0.01% |
+792
| New | +$66.5K |
|
|
PENG
299
Penguin Solutions Inc
PENG
$2.96B
| $73K | 0.01% |
+3,854
| New | +$57.6K |
|
300
Advance Auto Parts
AAP
$3.36B
| $72K | 0.01% |
+454
| New | +$70K |
|
Similar funds
MVG
NCM
FFGIM
PIM
HFG
SWM
ICM
SM
Vantage Consulting Group's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Vantage Consulting Group, which disclosed 1,884 positions worth $1.23B. Its ten largest holdings account for 94% of the portfolio.
Its largest position is Royalty Pharma: 21,477,282 shares worth $1.07B.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Technology and Consumer Discretionary.
- Vantage Consulting Group's largest Q4 2020 buy was Royalty Pharma: 21,477,282 shares worth $1.07B.
- Vantage Consulting Group's ten largest holdings make up 94% of its $1.23B portfolio in Q4 2020.
- Vantage Consulting Group disclosed 1,884 positions in Q4 2020, its first 13F filing on record.
Based on Vantage Consulting Group's 13F filing for Q4 2020, filed 12 Feb 2021.